A trial of long-acting release (LAR) formulation of exenatide to evaluate its glucose lowering effect in diabetes patient with dementia.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Mar 2016 New trial record